Editas Medicine Stock Current Valuation
| EDIT Stock | USD 1.37 0.03 2.24% |
Valuation analysis of Editas Medicine helps investors to measure Editas Medicine's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 921.9 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop (3.95) in 2025. Fundamental drivers impacting Editas Medicine's valuation include:
Undervalued
Today
Please note that Editas Medicine's price fluctuation is dangerous at this time. Calculation of the real value of Editas Medicine is based on 3 months time horizon. Increasing Editas Medicine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Editas Medicine's intrinsic value may or may not be the same as its current market price of 1.37, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.37 | Real 1.96 | Target 3.75 | Hype 1.39 | Naive 1.47 |
The intrinsic value of Editas Medicine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Editas Medicine's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Editas Medicine helps investors to forecast how Editas stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Editas Medicine more accurately as focusing exclusively on Editas Medicine's fundamentals will not take into account other important factors: Editas Medicine Company Current Valuation Analysis
Editas Medicine's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Editas Medicine Current Valuation | (109.38 M) |
Most of Editas Medicine's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Editas Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Current Valuation. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.
Click cells to compare fundamentals
Editas Current Valuation Historical Pattern
Today, most investors in Editas Medicine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Editas Medicine's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Editas Medicine current valuation as a starting point in their analysis.
Editas Medicine Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Editas Medicine has a Current Valuation of (109.38 Million). This is 100.76% lower than that of the Biotechnology sector and 102.35% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.66% higher than that of the company.
Editas Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.Editas Medicine is currently under evaluation in current valuation category among its peers.
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 4.1B | 1.8B | 609.1M | 769.5M | 692.6M | 1.0B | |
| Enterprise Value | 4.0B | 1.6B | 511.5M | 682.4M | 614.2M | 921.9M |
Editas Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (109.38 M) | ||||
| Shares Outstanding | 82.55 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 70.83 % | ||||
| Number Of Shares Shorted | 19.15 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 0.67 X | ||||
| Price To Sales | 1.79 X | ||||
| Revenue | 78.12 M | ||||
| Gross Profit | (158.43 M) | ||||
| EBITDA | (163.12 M) | ||||
| Net Income | (153.22 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 36.54 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (132.18 M) | ||||
| Short Ratio | 6.43 X | ||||
| Earnings Per Share | (2.54) X | ||||
| Target Price | 3.75 | ||||
| Number Of Employees | 265 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 110.61 M | ||||
| Total Asset | 499.15 M | ||||
| Retained Earnings | (1.23 B) | ||||
| Working Capital | 277.61 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 499.15 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.